Xenetic Biosciences Reports Q3 2025 Financial Results

Xenetic Biosciences, Inc. ( (XBIO) ) has released its Q3 earnings. Here is a breakdown of the information Xenetic Biosciences, Inc. presented to its investors.

Xenetic Biosciences, Inc. is a biopharmaceutical company based in Framingham, Massachusetts, specializing in innovative immuno-oncology technologies aimed at treating difficult cancers. The company’s proprietary DNase technology targets neutrophil extracellular traps to enhance the effectiveness of existing cancer treatments.

In its latest earnings report, Xenetic Biosciences highlighted a notable increase in royalty revenue, reaching approximately $1.03 million for the third quarter of 2025, compared to $614,243 in the same period last year. Despite this revenue growth, the company reported a net loss of $509,940 for the quarter, which is an increase from the $436,671 loss in the previous year.

Key financial metrics from the report include a decrease in cash reserves to $4.12 million from $6.17 million at the end of 2024, and an increase in total liabilities to $1.11 million. The company continues to invest heavily in research and development, with expenses in this area rising to $756,482 for the quarter.

Xenetic Biosciences is actively pursuing strategic alternatives to maximize shareholder value, including potential mergers or asset sales. The company remains focused on advancing its DNase technology into clinical trials for pancreatic carcinoma and other solid tumors, while also exploring additional funding opportunities to support its long-term initiatives.

Looking ahead, Xenetic Biosciences is optimistic about its prospects, with management confident in its ability to secure necessary capital and continue developing its promising DNase technology. The company is committed to maintaining its Nasdaq listing and exploring strategic partnerships to enhance its market position.